Argatroban, a direct thrombin inhibitor, successfully treated severe COVID-19 patients with acute ATIII deficiency, with confirmed thrombosis upon hospitalisation and resistance to the use of a prophylactic dose of low molecular weight heparin (LMWH). The gene discussed is SERPINC1; the disease is hyperinsulinemic hypoglycemia, familial, 4.